2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

4:30PM-6:00PM: Abstract Number: 1876

Effect of Discontinuation of Denosumab in Subjects with Rheumatoid Arthritis Treated with Glucocorticoids

4M114: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (1872–1877)

4:30PM-6:00PM: Abstract Number: 1883

Elucidating Pain Mechanisms in Polyarticular Juvenile Idiopathic Arthritis Patients

4M115: Pain Mechanisms – Basic & Clinical Science (1878–1883)

4:30PM-6:00PM: Abstract Number: 1855

Evaluating the OMERACT Definitions of Ultrasound Gout Structural Lesions in the Diagnosis of Gout

4M111: Imaging of Rheumatic Diseases I (1854–1859)

4:30PM-6:00PM: Abstract Number: 1874

Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results from the FRAME Clinical Trial

4M114: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (1872–1877)

4:30PM-6:00PM: Abstract Number: 1864

Gaps in Care for Patients with SLE: Data from the ACR’s RISE Registry

4M112: Measures of Healthcare Quality I: Digital Health Technologies – Tool for Improvement (1860–1865)

4:30PM-6:00PM: Abstract Number: 1873

Geisinger HiROC Performance 2017-2018: Continuing to Narrow the Post-Fracture Treatment Gap

4M114: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (1872–1877)

4:30PM-6:00PM: Abstract Number: 1866

Gene Expression Meta-Analysis Reveals Commonalities in Gene Activation and Enrichment of Immune Pathways and Cell Types in Dermatomyositis Target Tissues

4M113: Muscle Biology, Myositis & Myopathies I (1866–1871)

4:30PM-6:00PM: Abstract Number: 1912

High Dimensional Flowcytometric Profiling Distinguishes Psoriasis and Psoriatic Arthritis

4M121: Spondyloarthritis Including Psoriatic Arthritis – Clinical IV: Axial Spondyloarthritis Translational Research (1908–1913)

4:30PM-6:00PM: Abstract Number: 1857

High-resolution MRI Assessment of Flexor Tendon Pulleys in Psoriatic Arthritis for Disease Monitoring and Differentiation from Rheumatoid Arthritis Using a 16-channel Hand Coil

4M111: Imaging of Rheumatic Diseases I (1854–1859)

4:30PM-6:00PM: Abstract Number: 1891

Hydroxychloroquine Use Is Associated with a Lower Risk of Major Adverse Cardiovascular Events in Medicare Recipients with Rheumatoid Arthritis

4M117: RA – Treatments III: Cardiovascular Disease & Readmissions (1890–1895)

4:30PM-6:00PM: Abstract Number: 1904

IL-6 Receptor Inhibition in Primary Sjögren Syndrome : Results from a Randomized Multicenter Academic Double Blind Placebo-controlled Trial of Tocilizumab in 110 Patients

4M119: Sjögrenʼs Syndrome – Basic & Clinical Science (1902–1907)

4:30PM-6:00PM: Abstract Number: 1922

Improvement in Hepatitis B Screening Prior to Initiation of Biologic Therapy in the Pediatric Rheumatology Clinic

4M125: Pediatric Rheumatology: Outcomes & Quality of Life (1920–1925)

4:30PM-6:00PM: Abstract Number: 1865

Improving Lupus Care Index Documentation in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)

4M112: Measures of Healthcare Quality I: Digital Health Technologies – Tool for Improvement (1860–1865)

4:30PM-6:00PM: Abstract Number: 1863

Improving Pneumococcal Vaccination Rates in High Risk Rheumatology Patients

4M112: Measures of Healthcare Quality I: Digital Health Technologies – Tool for Improvement (1860–1865)

4:30PM-6:00PM: Abstract Number: 1914

Increased Risk of Progression to Lupus Nephritis for Lupus Patients with Elevated Interferon Signature

4M120: SLE – Clinical IV: Lupus Nephritis (1914–1919)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].